A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Recruiting · NCT06476808 · Interventional (participants receive a specific treatment) · Lead sponsor: Bristol-Myers Squibb
View the official record on ClinicalTrials.gov →Interventions studied
BMS-986463
What this trial is about
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
- Participants must have an unresectable/metastatic carcinoma.
Exclusion criteria
- Participants must not have Leptomeningeal metastases.
- Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
- Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where it is running
17 locations listed across 4 US states.
- USC/Norris Comprehensive Cancer Center - Los Angeles, California, United States
- Valkyrie Clinical Trials - Los Angeles, California, United States
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack, New Jersey, United States
- Local Institution - 0045 - Columbus, Ohio, United States
- Local Institution - 0046 - Dallas, Texas, United States
- Local Institution - 0049 - Houston, Texas, United States
- Local Institution - 0041 - Avda.Pio XII 36,, Spain
- Local Institution - 0035 - Lyon, France
- Local Institution - 0033 - Milan, Italy
- Local Institution - 0032 - Milan, Italy
- Local Institution - 0036 - Bordeaux, Aquitaine, France
- Local Institution - 0042 - Barcelona, Barcelona [Barcelona], Spain
- BC Cancer Vancouver - Vancouver, British Columbia, Canada
- Princess Margaret Cancer Centre - Toronto, Ontario, Canada
- Centre Hospitalier de l'Université de Montréal - Montreal, Quebec, Canada
- Jewish General Hospital - Montreal, Quebec, Canada
- Local Institution - 0031 - Villejuif, Val-de-Marne, France